Japanese Pharmacology & Therapeutics（JPT）
Vol.27 Suppl.7 1999
*With abstract in English **In English
Opening Remarks
T. Namihisa
Jpn Pharmacol Ther 1999 27(Suppl.7) s1471
1. Suicide gene therapy of hepatocellular carcinoma using EBV-based episomal vector/dendrimer complex in vitro
Y. Harada, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1479-83
2. Analysis of intrahepatic invasion and metastasis of hepatocellular carcinoma in normal and cirrhotic livers using fluorescent dye-labeled hepatocellular carcinoma cells
M. Yamazaki, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1485-90
3. Protective effect of very low dose-LPS pre-treatment on experimental acute hepatic injury
T. Kono, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1491-3
4. Gender-associated differences in concanavalin A-induced hepatitis in mice
K. Nakamura, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1495-7
5. Effect of nitric oxide on hepatic cytochrome P450 in endotoxemia
S. Takemura, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1499-503
6. Nitric oxide-induced inhibition of cytochrome P450
Y. Minamiyama, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1505-10
【Discussion1～6】
Jpn Pharmacol Ther 1999 27(Suppl.7) s1511-4
7. Distribution of proliferative sinusoidal endothelial cells in liver regeneration after partial hepatectomy in rats
E. Taniguchi, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1515-7
8. Quantitative demonstration of porto―systemic shunt by alterd 201 thallium chloride portal scintigraphy in patients with chronic liver disease
H. Kato, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1519-23
9. Stimulatory effect of central thyrotropin-releasing hormone on hepatic blood flow
M. Yoneda, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1525-8
10. Serum matrix metalloproteinase-2 and liver fibrosis
Y. Murawaki, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1529-34
11. Significance of serum thioredoxin in patients with hepatitis C virus
-related chronic liver disease
Y. Sumida, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1535-8
12. Cysteine catabolism in rat hepatocytes after short-term culture
K. Matsumaru, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1539-43
13. Heterogeneity of gap junctional channels in hepatic lobule
M. Iwai, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1545-6
【Discussion7～13】
Jpn Pharmacol Ther 1999 27(Suppl.7) s1547-51
14. Perticipation of IL-18 in human cholestatic cirrhosis and acute rejection
－Analysis in living donor liver transplantation－
T. Yagi, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1553-60
15. Effect of immunosuppressants on bile acid kinetics
－Comparative study of cyclosporine with tacrolimus－
K. Mizuta, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1561-6
16. Analysis of bilirubin and bile acid fractions in serum and bile juice after living related liver transplantation
Y. Akamatsu, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1567-73*
17. Coagulopathy after bilirubin adsorption in a living related partial liver transplant recipient
H. Ishida, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1575-8*
18. Primary sclerosing cholangitis－3 cases report－
C. Yasui, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1579-84
19. Living donor liver transplantation for alagille's syndrome
T. Tsuchiya, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1585-9*
20. Living related liver transplantation in 2 families of Byler's disease
T. Suzuki, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1591-5*
【Discussion 14～20】
Jpn Pharmacol Ther 1999 27(Suppl.7) s1597-601
21. Induction of heme oxygenase-1 attenuates hepatobiliary dysfunction elicited by cold ischemia and reperfusion in the rat liver
－Role of bilirubin－
Y. Kato, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1603-4
22. Effects of UDCA on unusual trihydroxy bile acids in the urine of patients with liver diseases
T. Nakashima, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1605-8
23. Effects of phalloidin on biliary excretion of cholephilic compounds
A.Sato, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1609-11
24. Effect of obstructive cholestasis on liver plasma membrane fluidity
－Relation to phospholipid molecular species of lipid bilayers－
H. Hyogo, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1613-5
25. Effects of bilirubin ditaurate on liver canalicular membrane fluidity and lipid composition
T. Kajihara, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1617-8
26. Effect of enzyme induction on billiary excretion of irinotecan hydrochloride (CPT―11), and its active metabolite (SN―38)
M. Horikawa, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1619-22
27. Prediction for drug interaction via hepatic transporters
Y. Kato, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1623-6
Discussion【21～27】
Jpn Pharmacol Ther 1999 27(Suppl.7) s1627-9
28. cMOAT mutations in two patients with Dubin―Johnson syndrome(DJS)
Y. Imaizumi, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1631-4*
29. Inhibitory effect of quindine and quinine on the Oatp1― and Oatp2― mediated transport
Y. Shitara, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1635-41*
30. Analysis of the mechanism for the induction of MRP3
T. Takada et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1643-6
31. Characterization the mechanism for the biliary excretion of bile acids across the canalicular membrane
H. Akita et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1647-50
32. Clinical usefulness of conjugated bilirubin measurement
T. Itoh, et al.
Jpn Pharmacol Ther 1999 27(Suppl.7) s1651-4
【Discussion 28～32】
Jpn Pharmacol Ther 1999 27(Suppl.7) s1655-6
Bilirubin for a laboratory test
M. Totani
Jpn Pharmacol Ther 1999 27(Suppl.7) s1657-8
Closing Remarks
S. Kasai
Jpn Pharmacol Ther 1999 27(Suppl.7) s1659